Human NADPH-Cytochrome P450 Reductase Overexpression Does Not Enhance the Aerobic Cytotoxicity of Doxorubicin in Human Breast Cancer Cell Lines

Cancer Research

Volumn 63, Issue 20, 2003, Pages 6914-6919

  Ramji, Shairoz ^a   Lee, Chunja ^a   Inaba, Tadanobu ^a   Patterson, Adam V ^b   Riddick, David S ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; DOXORUBICIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; TIRAPAZAMINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CHEMOSENSITIVITY; CYTOTOXICITY; DRUG CYTOTOXICITY; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LIVER MICROSOME; LYMPHOBLASTOID CELL; PRIORITY JOURNAL;

AEROBIOSIS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; HUMANS; INDOLES; NADPH-FERRIHEMOPROTEIN REDUCTASE; PYRROLES; TRANSFECTION;

EID: 0142157665     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Booser, D. J., and Hortobagyi, G. N. Anthracycline antibiotics in cancer therapy: focus on drug resistance. Drugs, 47: 223-258, 1994.
2. Gewirtz, D. A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem. Pharmacol., 57: 727-741, 1999.
3. Forrest, G. L., and Gonzalez, B. Carbonyl reductase. Chem. Biol. Interact., 129: 21-40, 2000.
4. Forrest, G. L., Gonzalez, B., Tseng, W., Li, X. L., and Mann, J. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res., 60: 5158-5164, 2000.
5. Cummings, J., Allan, L., Willmott, N., Riley, R., Workman, P., and Smyth, J. F. The enzymology of doxorubicin quinone reduction in tumour tissue. Biochem. Pharmacol., 44: 2175-2183, 1992.
6. Bachur, N. R., Gordon, S. L., and Gee, M. V. Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation. Mol. Pharmacol., 13: 901-910, 1977.
7. Sinha, B. K., Katki, A. G., Batist, G., Cowan, K. H., and Myers, C. E. Adriamycin-stimulated hydroxyl radical formation in human breast tumor cells. Biochem. Pharmacol., 36: 793-796, 1987.
8. Minotti, G., Cairo, G., and Monti, E. Role of iron in anthracycline cardiotoxicity: new tunes for an old song? FASEB J., 13: 199-212, 1999.
9. Singal, P., Li, T. M., Kumar, D., Danelisen, I., and Iliskovic, N. Adriamycin-induced heart failure: mechanisms and modulation. Mol. Cell. Biochem., 207: 77-86, 2000.
10. Ghezzi, P., Donelli, M. G., Pantarotto, C., Facchinetti, T., and Garattini, S. Evidence for covalent binding of adriamycin to rat liver microsomal proteins. Biochem. Pharmacol., 30: 175-177, 1981.
11. Zeman, S. M., Phillips, D. R., and Crothers, D. M. Characterization of covalent Adriamycin-DNA adducts. Proc. Natl. Acad. Sci. USA, 95: 11561-11565, 1998.
12. Cummings, J., Bartoszek, A., and Smyth, J. F. Determination of covalent binding to intact DNA, RNA, and oligonucleotides by intercalating anticancer drugs using high-performance liquid chromatography: studies with doxorubicin and NADPH cytochrome P450 reductase. Anal. Biochem., 194: 146-155, 1991.
13. Taatjes, D. J., Fenick, D. J., Gaudiano, G., and Koch, T. H. A redox pathway leading to the alkylation of nucleic acids by doxorubicin and related anthracyclines: application to the design of antitumor drugs for resistant cancer. Curr. Pharm. Des., 4: 203-218, 1998.
14. Taatjes, D. J., Fenick, D. J., and Koch, T. H. Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines. Chem. Res. Toxicol., 12: 588-596, 1999.
15. Bachur, N. R., Gordon, S. L., Gee, M. V., and Kon, H. NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc. Natl. Acad. Sci. USA, 76: 954-957, 1979.
16. Berlin, V., and Haseltine, W. A. Reduction of Adriamycin to a semiquinone-free radical by NADPH cytochrome P-450 reductase produces DNA cleavage in a reaction mediated by molecular oxygen. J. Biol. Chem., 256: 4747-4756, 1981.
17. Komiyama, T., Kikuchi, T., and Sugiura, Y. Generation of hydroxyl radical by anticancer quinone drugs, carbazilquinone, mitomycin C, aclacinomycin A and Adriamycin, in the presence of NADPH-cytochrome P450 reductase. Biochem. Pharmacol., 31: 3651-3656, 1982.
18. Bartoszek, A., and Wolf, C. R. Enhancement of doxorubicin toxicity following activation by NADPH cytochromc P450 reductase. Biochem. Pharmacol., 43: 1449-1457, 1992.
19. Bartoszek, A. Metabolic activation of Adriamycin by NADPH-cytochrome P450 reductase: overview of its biological and biochemical effects. Acta Biochim. Pol., 49: 323-331, 2002.
20. Sawamura, A. O., Aoyama, T., Tamakoshi, K., Mizuno, K., Suganuma, N., Kikkawa, F., and Tomoda, Y. Transfection of human cytochrome P-450 reductase cDNA and its effect on the sensitivity to toxins. Oncology (Basel), 53: 406-411, 1996.
21. Schmalix, W. A., Lang, D., Schneider, A., Bocker, R., Greim, H., and Doehmer, J. Stable expression and coexpression of human cytochrome P450 oxidoreductase and cytochrome P450 1A2 in V79 Chinese hamster cells: sensitivity to quinones and biotransformation of 7-alkoxyresorufins and triazines. Drug Metab. Dispos., 24: 1314-1319, 1996.
22. Goeptar, A. R., Koppele, J. M. T., Lamme, E. K., Pique, J. M., and Vermeulen, N. P. E. Cytochrome P450-2B1-mediated one-electron reduction of Adriamycin: a study with rat liver microsomes and purified enzymes. Mol. Pharmacol., 44: 1267-1277, 1993.
23. Goeptar, A. R., Groot, E. J., Scheerens, H., Commandeur, J. N. M., and Vermeulen, N. P. E. Cytotoxicity of mitomycin C and Adriamycin in freshly isolated rat hepatocytes: the role of cytochrome P450. Cancer Res., 54: 2411-2418, 1994.
24. Goeptar, A. R., Tekoppele, J. M., Glatt, H. R., Groot, E. J., Seidel, A., Barrenscheen, M., Wolfel, C., Doehmer, J., and Vermeulen, N. P. E. The cytotoxicity of mitomycin C and Adriamycin in genetically engineered V79 cell lines and freshly isolated rat hepatocytes. Chem. Biol. Interact., 97: 149-168, 1995.
25. Niitsu, N., Kasukabe, T., Yokoyama, A., OkabeKado, J., Yamamoto-Yamaguchi, Y., Umeda, M., and Honma, Y. Anticancer derivative of butyric acid (pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity. Mol. Pharmacol., 58: 27-36, 2000.
26. Fitzsimmons, S. A., Workman, P., Grever, M., Paull, K., Camalier, R., and Lewis, A. D. Reductase enzyme expression across the National Cancer Institute tumor cell line panel: correlation with sensitivity to mitomycin C and E09. J. Natl. Cancer Inst. (Bethesda), 88: 259-269, 1996.
27. Yu, L. J., Matias, J., Scudiero, D. A., Hite, K. M., Monks, A., Sausville, E. A., and Waxman, D. J. P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab. Dispos., 29: 304-312, 2001.
28. Chen, L., and Waxman, D. J. Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr. Pharm. Des., 8: 1405-1416, 2002.
29. Patterson, A. V., Saunders, M. P., Chinje, E. C., Talbot, D. C., Harris, A. L., and Stratford, I. J. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br. J. Cancer, 76: 1338-1347, 1997.
30. Sumida, A., Kinoshita, K., Fukuda, T., Matsuda, H., Yamamoto, I., Inaba, T., and Azuma, J. Relationship between mRNA levels quantified by reverse transcription-competitive PCR and metabolic activity of CYP3A4 and CYP2E1 in human liver. Biochem. Biophys. Res. Commun., 262: 499-503, 1999.
31. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193: 265-275, 1951.
32. Alley, M. C., Scudiero, D. A., Monks, A., Hursey, M. L., Czerwinski, M. J., Fine, D. L., Abbott, B. J., Mayo, J. G., Shoemaker, R. H., and Boyd, M. R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res., 48: 589-601, 1988.
33. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of baeteriophage T4. Nature (Lond.), 227: 680-685, 1970.
34. Towbin, H., Staehelin, T., and Gordon, J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA, 76: 4350-4354, 1979.
35. Strobel, H. W., and Dignam, J. D. Purification and properties of NADPH-cytochrome P-450 reductase. Methods Enzymol., 52: 89-96, 1978.
36. Minotti, G. NADPH- and Adriamycin-dependent microsomal release of iron and lipid peroxidation. Arch. Biochem. Biophys., 277: 268-276, 1990.
37. O'Donnell, V. B., Smith, G. C. M., and Jones, O. T. G. Involvement of phenyl radicals in iodonium compound inhibition of flavoenzymes. Mol. Pharmacol., 46: 778-785, 1994.
38. McManus, M. E., Hall, P. D., Stupans, I., Brennan, J., Burgess, W., Robson, R., and Birkett, D. J. Immunohistochemical localization and quantitation of NADPH-cytochrome P-450 reductase in human liver. Mol. Pharmacol., 32: 189-194, 1987.
39. Yamano, S., Aoyama, T., McBride, O. W., Hardwick, J. P., Gelboin, H. V., and Gonzalez, F. J. Human NADPH-P450 oxidoreductase: complementary DNA cloning, sequence and vaccinia virus-mediated expression and localization of the CYPOR gene to chromosome 7. Mol. Pharmacol., 35: 83-88, 1989.
40. Shephard, E. A., Palmer, C. N., Segall, H. J., and Phillips, I. R. Quantification of cytochrome P450 reductase gene expression in human tissues. Arch. Biochem. Biophys., 294: 168-172, 1992.
41. Pearce, R. E., McIntyre, C. J., Madan, A., Sanzgiri, U., Draper, A. J., Bullock, P. L., Cook, D. C., Burton, L. A., Latham, J., Nevins, C., and Parkinson, A. Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Arch. Biochem. Biophys., 331: 145-169, 1996.
42. Doroshow, J. H., Akman, S., Chu, F-F., and Esworthy, S. Role of the glutathione-glutathione peroxidase cycle in the cytotoxicity of the anticancer quinones. Pharmacol. Ther., 47: 359-370, 1990.
43. Sinha, B. K., Katki, A. G., Batist, G., Cowan, K. H., and Myers, C. E. Differential formation of hydroxyl radicals by Adriamycin in sensitive and resistant MCF-7 human breast tumor cells: implications for the mechanism of action. Biochemistry, 26: 3776-3781, 1987.
44. Sinha, B. K., Mimnaugh, E. G., Rajagopalan, S., and Myers, C. E. Adriamycin activation and oxygen free radical formation in human breast tumor cells: protective role of glutathione peroxidase in adriamycin resistance. Cancer Res., 49: 3844-3848, 1989.
45. Mimnaugh, E. G., Dusre, L., Atwell, J., and Myers, C. E. Differential oxygen radical susceptibility of Adriamycin-sensitive and -resistant MCF-7 human breast tumor cells. Cancer Res., 49: 8-15, 1989.
46. Doroshow, J. H., Akman, S., Esworthy, S., Chu, F. F., and Burke, T. Doxorubicin resistance conferred by selective enhancement of intracellular glutathione peroxidase or superoxide dismutase content in human MCF-7 breast cancer cells. Free Radic. Res. Commun., 12-13: 779-781, 1991.
47. Svingen, B. A., and Powis, G. Pulse radiolysis studies of antitumor quinones: radical lifetimes, reactivity with oxygen, and one-electron reduction potentials. Arch. Biochem. Biophys., 209: 119-126, 1981.
48. Patterson, A. V., Saunders, M. P., Chinje, E. C., Patterson, L. H., and Stratford, I. J. Enzymology of tirapazamine metabolism: a review. Anti-Cancer Drug Des., 13: 541-573, 1998.
49. Delahoussaye, Y. M., Evans, J. W., and Brown, J. M. Metabolism of tirapazamine by multiple reductases in the nucleus. Biochem. Pharmacol., 62: 1201-1209, 2001.
50. Patterson, A. V., Barham, H. M., Chinje, E. C., Adams, G. E., Harris, A. L., and Stratford, I. J. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br. J. Cancer, 72: 1144-1150, 1995.
51. Phillips, R. M., and Clayton, M. R. Plateau-phase cultures: an experimental model for identifying drugs which are bioactivated within the microenvironment of solid tumours. Br. J. Cancer, 75: 196-201, 1997.